H2-T10 Inhibitors
Chemical inhibitors of H2-T10 work by disrupting various stages of the antigen processing and presentation pathway. Concanamycin A and Bafilomycin A1 target the vacuolar ATPase (V-ATPase), an enzyme complex that is crucial for the acidification of endosomes and lysosomes. This acidification is necessary for the optimal activity of H2-T10 in antigen presentation. By inhibiting V-ATPase, these chemicals ensure that the pH within the endosomes remains more neutral than required for H2-T10 to function effectively, thereby inhibiting its ability to present antigens. Similarly, Monensin disrupts intracellular ion gradients and pH by exchanging sodium ions for protons across biological membranes, which also affects the acidification process necessary for H2-T10 function. Omeprazole, although primarily working on gastric acid secretion, operates through a mechanism that could similarly affect vesicular acidification by inhibiting H+/K+-ATPase, suggesting a possible indirect inhibition of H2-T10.
Proteasome inhibitors like Lactacystin, Epoxomicin, and MG-132 interfere with the proteolytic degradation of proteins into peptides. For H2-T10 to present antigens, proteins must first be degraded into peptides that can be bound and presented on the cell surface. By blocking proteasome function, these inhibitors prevent the generation of peptides necessary for H2-T10 to function, thereby inhibiting its activity. In the same vein, Leupeptin and E-64 inhibit serine and cysteine proteases, respectively, which are involved in antigen processing prior to presentation by H2-T10. The inhibition of these enzymes disrupts the normal proteolytic cleavage of proteins into the peptide fragments that are essential for H2-T10-mediated antigen presentation. Lastly, Z-VAD-FMK, a pan-caspase inhibitor, may not directly act on antigen processing enzymes but can alter the intracellular signaling environment, which is necessary for the regulation of proteins like H2-T10 involved in the antigen presentation pathway.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Concanamycin A, as a specific inhibitor of V-ATPase, disrupts the acidification of endosomes. Since acidification is crucial for the function of H2-T10 in antigen processing, inhibition of V-ATPase would directly impair the ability of H2-T10 to present antigens, leading to its functional inhibition. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Similar to Concanamycin A, Bafilomycin A1 targets V-ATPase. By inhibiting this pump, the chemical ensures that the necessary acidic environment for H2-T10's antigen presentation is not maintained, thus functionally inhibiting H2-T10. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is a proteasome inhibitor that interferes with the degradation of proteins into peptides, which are essential for antigen presentation by H2-T10. By blocking this process, Lactacystin effectively inhibits the functionality of H2-T10. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin, another proteasome inhibitor, would hinder the proteolytic processing that is essential for the generation of peptides that H2-T10 presents, thus functionally inhibiting the protein. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor that would prevent the breakdown of proteins into peptides that H2-T10 needs to present, thereby functionally inhibiting H2-T10. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $73.00 $148.00 $316.00 $499.00 $1427.00 $101.00 | 19 | |
Leupeptin inhibits serine and cysteine proteases, which play a role in the processing of antigens prior to their presentation by H2-T10. The inhibition of these enzymes would therefore result in a functional inhibition of H2-T10. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
E-64 is an inhibitor of cysteine proteases. By inhibiting these enzymes, E-64 would prevent the proper processing of antigens for presentation by H2-T10, leading to its functional inhibition. | ||||||
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $75.00 | 256 | |
Z-VAD-FMK is a pan-caspase inhibitor that can affect the processing of inflammatory cytokines. As cytokines can regulate the activity of proteins involved in antigen presentation, Z-VAD-FMK may lead to a functional inhibition of H2-T10 through an indirect pathway, by modulating the intracellular environment and signaling in which H2-T10 operates. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is an ionophore that alters intracellular ion gradients and pH by exchanging Na+ for H+ across biological membranes. This alteration can impact the maturation of endosomes and their acidification status, which is crucial for H2-T10's function in antigen presentation, leading to a functional inhibition of H2-T10. | ||||||
Omeprazole | 73590-58-6 | sc-202265 | 50 mg | $67.00 | 4 | |
Omeprazole, a proton pump inhibitor, would reduce vesicular acidification by inhibiting H+/K+-ATPase in the stomach. While primarily affecting gastric acid production, its mode of action suggests that it could also reduce the acidification needed for H2-T10's antigen presentation function, thereby functionally inhibiting H2-T10 in a similar way to V-ATPase inhibitors. | ||||||